Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for banking industry professionals · Friday, March 29, 2024 · 699,701,227 Articles · 3+ Million Readers

Fabry Disease Markets 2018-2028: 10 Year Forecast In 21 Major Markets

Dublin, July 16, 2018 (GLOBE NEWSWIRE) -- The "Epiomic Epidemiology Series: Fabry Disease Forecast In 21 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

The Epiomic Epidemiology Series Forecast Report on Fabry Disease in 21 Major Markets

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (aGLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Austria, Portugal, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

  • Angiokeratoma
  • Cornea verticillata (corneal whorling)
  • Hearing loss
  • Tinnitus
  • Proteinuria
  • Cardiac hypertrophy & arrhythmias
  • Sweating dysfunction

Reasons to buy

  • Able to quantify patient populations in global Fabry disease market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Fabry disease and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Fabry disease prevalent population.
  • Identify sub-populations within Fabry disease which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Fabry disease patients.

Key Topics Covered:

  1. Introduction
  2. Cause Of The Disease
  3. Risk Factors & Prevention
  4. Diagnosis Of The Disease
  5. Variation By Geography/Ethnicity
  6. Disease Prognosis & Clinical Course
  7. Key Comorbid Conditions / Features Associated With The Disease
  8. Methodology For Quantification Of Patient Numbers
  9. Top-Line Prevalence For Fabry Disease
  10. Features Of Fabry Disease Patients
  11. Abbreviations Used In The Report
  12. Other Services & Solutions
  13. Reports & Publications
  14. Online Epidemiology Databases
  15. Online Pharmaceutical Pricing Database
  16. References
  17. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/2fbkh3/fabry_disease?w=12

                    
                    
                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Endocrine and Metabolic Disorders Drugs
                    

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release